Patents by Inventor Mohammad Luqman

Mohammad Luqman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170081416
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Application
    Filed: August 19, 2016
    Publication date: March 23, 2017
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Li Long, Mohammad Luqman (deceased), Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
  • Publication number: 20150175705
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: March 3, 2015
    Publication date: June 25, 2015
    Inventors: Jason Damiano, Mohammad Luqman, Linda Masat, Amer Mirza, Genevieve Nonet, Daniel Bedinger
  • Patent number: 9005614
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 14, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • Publication number: 20150086991
    Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 26, 2015
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AG
    Inventors: Sharon Lea Aukerman, Mohammad Luqman
  • Patent number: 8926979
    Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: January 6, 2015
    Assignees: Novartis AG, XOMA Technology Ltd.
    Inventors: Sharon Lea Aukerman, Mohammad Luqman
  • Publication number: 20140205602
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 24, 2014
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
  • Publication number: 20130230528
    Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Application
    Filed: December 17, 2012
    Publication date: September 5, 2013
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AG
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Publication number: 20130011405
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 10, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
  • Patent number: 8337851
    Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: December 25, 2012
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Patent number: 8333970
    Abstract: Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: December 18, 2012
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Patent number: 8277810
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 2, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst
  • Publication number: 20110150760
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: November 22, 2010
    Publication date: June 23, 2011
    Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: JASON DAMIANO, MOHAMMAD LUQMAN, DANIEL BEDINGER, LINDA MASAT, AMER MIRZA, GENEVIEVE NONET
  • Patent number: 7867493
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: January 11, 2011
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • Publication number: 20110002934
    Abstract: This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.
    Type: Application
    Filed: November 7, 2008
    Publication date: January 6, 2011
    Inventors: Mohammad Luqman, Sherna Budhabhatti, Yongyu Wang, Seema Kantak, Ssucheng J. Hsu, Amer M. Mirza
  • Publication number: 20090202531
    Abstract: Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided.
    Type: Application
    Filed: November 1, 2006
    Publication date: August 13, 2009
    Applicants: Novartis AG, XOMA Technology Ltd.
    Inventors: Sharon Lea Aukerman, Mohammad Luqman
  • Publication number: 20090117111
    Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.
    Type: Application
    Filed: November 1, 2006
    Publication date: May 7, 2009
    Inventors: Sharon Lea Aukerman, Mohammad Luqman
  • Publication number: 20090041773
    Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Application
    Filed: May 18, 2006
    Publication date: February 12, 2009
    Applicants: Novartis Vaccines and Diagnostics , Inc., XOMA Technology Ltd.
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Publication number: 20080292620
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: August 17, 2007
    Publication date: November 27, 2008
    Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • Publication number: 20080274118
    Abstract: Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Application
    Filed: May 18, 2006
    Publication date: November 6, 2008
    Applicants: Novartis Vaccines and Diagnostics, Inc., XOMA Technology Ltd.
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Publication number: 20080254026
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Application
    Filed: October 31, 2007
    Publication date: October 16, 2008
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes